Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Transcriptomic profiling in Malawian patients with acute hypersensitivity reactions to Nevirapine

ABSTRACT: Nevirapine is a non-nucleoside reverse transcriptase inhibitor, a class of antiretroviral drug, used for the treatment of HIV-1 infection. Despite its wide use, nevirapine treatment has been associated with a significant incidence of different kind of hypersensitivity reactions (HSRs). We used microarrays to find significant genes that can relate to Nevirapine-persuaded hypersensitivity reactions in ‘acute’ patients compared to ‘recovered’ and/or ‘tolerant’ patients.

ORGANISM(S): Homo sapiens

PROVIDER: GSE42436 | GEO | 2015/11/30

SECONDARY ACCESSION(S): PRJNA181968

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Prospective Analysis of Hypersensitivity Reactions to Oxaliplatin

Project description:This research study will examine how often hypersensitivity, or allergic reactions, occur in patients receiving the chemotherapy medication oxaliplatin. Hypersensitivity reactions can vary from a transient skin rash and fever to more severe symptoms such as shortness of breath, chest tightness, and a more severe allergic reaction that can affect blood pressure called anaphylaxis. We will be examining how often hypersensitivity reactions occur and how severe the reactions are when they occur. We will also examine whether there are factors that place people at risk for developing hypersensitivity reactions to oxaliplatin. In an optional portion to this study, we will examine whether allergy skin testing can predict whether someone will develop a hypersensitivity reaction. Participants who develop a moderate to severe allergic reaction to oxaliplatin will be invited to participate in an additional portion of the study examining a desensitization process. This part of the study will examine whether a desensitization process can prevent future hypersensitivity reactions to oxaliplatin in patients who previously developed moderate to severe hypersensitivity reactions and allow therapy with oxaliplatin to continue.

| 2067027 | ecrin-mdr-crc

Investigating delayed-onset Drug Hypersensitivity Reactions Prospectively

Project description:Investigating delayed-onset Drug Hypersensitivity Reactions Prospectively

| PRJNA994264 | ENA

Investigating delayed-onset Drug Hypersensitivity Reactions Prospectively

Project description:Investigating delayed-onset Drug Hypersensitivity Reactions Prospectively

| PRJNA994263 | ENA

Gene expression profiles in drug-induced hypersensitivity reactions with cutaneous involvement

2009-10-01 | GSE12829 | GEO

Gene expression profiles in drug-induced hypersensitivity reactions with cutaneous involvement

Project description:Hypersensitivity reactions to medications constitute a growing problem in the clinical practice. In order to study the molecular basis underlying the pathogenesis of non-immediate hypersensitivity reactions to drugs, we characterized the gene expression profiles of PBMCs isolated from patients during the acute phase and upon resolution of the clinical symptoms using a cDNA array technology. Eighty five genes were found to be differentially expressed during the acute phase of drug-induced delayed hypersensitivity reactions. Furthermore, ninety two genes with distinct expression patterns during the acute phase of severe and benign diseases were identified. Keywords: Comparison between disease and healty status Expression profiles of 11835 genes were analyzed in peripheral blood mononuclear cells from 13 patients with different clinical entities . Two samples were analyze from each patient. The first blood sample was drawn during the acute phase of the disease. The second blood sample was obtained upon resolutin of the clinical symptoms. The ratio between gene expression levels in both samples was calculated for each patient.

2009-10-01 | E-GEOD-12829 | biostudies-arrayexpress

Carbamazepine-induced hypersensitivity reactions in Europeans

Project description:An antiepileptic drug carbamazepine is well tolerated by the majority of patients, but can cause severe and potentialy fatal hypersensitivity reactions in a small number of individuals. The aim of this study was to identify genetic predictors of hypersensitivity reactions to carbamazepine. We undertook a genome-wide association study (GWAS) in 22 patients of European ancestry with carbamazepine-induced hypersensitivity syndrome (HSS) and compared our data with genotypes from a healthy population within the WTCCC. We performed imputation of classical HLA alleles according to a recently described method (Science. 2010 Dec 10;330(6010):1551-7. Epub 2010 Nov 4). GWAS statistical analysis was performed using logistic regression with an additive model of inheritance.

| EGAS00000000037 | EGA

Assessment and Prediction of Cetuximab-Induced Hypersensitivity Reactions Using Cetuximab Specific IgE Detection

Project description:1. Background Cetuximab (trade name Erbitux) is a murine-human chimeric monoclonal antibody to human epidermal growth factor receptor (EGFR). This drug has been used as a treatment for colorectal cancer and head and neck cancer. It is known that allergic reactions can occur in more than 5% of the patients, although the side effects are relatively low compared with other chemotherapeutic agents. It is known that cetuximab can induce hypersensitivity even at the first administration, unlike other anticancer drugs. In this study, we aimed to establish a model to predict patients with hypersensitivity reaction before administration of cetuximab and to provide safe chemotherapy. 2. Recruitment method and consent procedure The study is designed for analysis patients scheduled for administration of cetuximab for the first time. Patients matching the selection and exclusion criteria with voluntary agreement to the study will be enrolled. Enrolled patients will be tested for skin prick test and serum sIgE before cetuximab administration.

| 2269895 | ecrin-mdr-crc

Analysis of human leukocyte antigen (HLA) allotype-specific response in abacavir-exposed keratinocyte

Project description:Abacavir, a nucleoside reverse-transcriptase inhibitor used for the treatment of human immunodeficiency virus (HIV) infection, develops hypersensitivity in patients carrying HLA-B*57:01 allele through drug antigen presentation. We found that abacavir exposure induced HLA allotype-specific innate immune response in keratinocyte derived from HLA-B*57:01 transgenic mice. Therefore, the mechanism of the novel response was analyzed comprehensively.

2018-03-01 | GSE110394 | GEO

A validation study of preventing oxaliplatin-induced hypersensitivity reactions by dexamethasone. (AVOID)

Project description:Interventions: Dexamethasone 13.2mg/body i.v.(day1) Oxaliplatin 130mg/m2 i.v. (day1) Bevaciumab 7.5mg/Kg i.v. (day1) Capecitabine2,000mg/m2,p.o.(day1-14) to be repeated every 3 weeks Primary outcome(s): Hypersensitivity reaction incidence Study Design: Single arm Non-randomized

| 2625136 | ecrin-mdr-crc

DNaseI sensitivity/hypersensitivity

Project description:DNaseI sensitivity/hypersensitivity

| PRJNA101147 | ENA